Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab
作者： Ronan J. Kelly , Corey Carter , Giuseppe Giaccone
关键词:
摘要:
elsevier.com
sci-hub.se 参考文章(25)
Lee M. Krug, Vincent A. Miller, Jyoti Patel, John Crapanzano, Christopher G. Azzoli, Jorge Gomez, Mark G. Kris, Robert T. Heelan, Barbara Pizzo, Leslie Tyson, Christine Sheehan, Jeffrey S. Ross, Ennapadam Venkatraman, Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma Cancer. ,vol. 104, pp. 2149- 2155 ,(2005) , 10.1002/CNCR.21428
C. Papila, H. Uzun, H. Balci, H. Zerdali, C. Sezgin, Günay Can, H. Yanardag, Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors Medical Oncology. ,vol. 26, pp. 151- 156 ,(2009) , 10.1007/S12032-008-9098-3
Ralph G Zinner, Bonnie S Glisson, Frank V Fossella, Katherine M.W Pisters, Merril S Kies, Pamela M Lee, Erminia Massarelli, Bradley Sabloff, Herbert A Fritsche, Jae Y Ro, Nelson G Ordonez, Hai T Tran, Ying Yang, Terry L Smith, Robert D Mass, Roy S Herbst, Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease Lung Cancer. ,vol. 44, pp. 99- 110 ,(2004) , 10.1016/J.LUNGCAN.2003.09.026
Roy S. Herbst, Angela M. Davies, Ronald B. Natale, Thao P. Dang, Joan H. Schiller, Linda L. Garland, Vincent A. Miller, David Mendelson, Annick D. Van den Abbeele, Yulia Melenevsky, Daniel J. de Vries, David A. Eberhard, Benjamin Lyons, Stuart G. Lutzker, Bruce E. Johnson, Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 13, pp. 6175- 6181 ,(2007) , 10.1158/1078-0432.CCR-07-0460
D. Graus-Porta, ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling The EMBO Journal. ,vol. 16, pp. 1647- 1655 ,(1997) , 10.1093/EMBOJ/16.7.1647
Haruhiko Nakamura, Norihito Kawasaki, Masahiko Taguchi, Kazuyuki Kabasawa, Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer. ,vol. 103, pp. 1865- 1873 ,(2005) , 10.1002/CNCR.20957
David H. Johnson, Carlos L. Arteaga, Gefitinib in Recurrent Non–Small-Cell Lung Cancer: An IDEAL Trial? Journal of Clinical Oncology. ,vol. 21, pp. 2227- 2229 ,(2003) , 10.1200/JCO.2003.04.001
Gerald Clamon, James Herndon, Jeffrey Kern, Ramaswamy Govindan, Jennifer Garst, Dorothy Watson, Mark Green, , Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. ,vol. 103, pp. 1670- 1675 ,(2005) , 10.1002/CNCR.20950
Fred R Hirsch, Wilbur A Franklin, Robert Veve, Marileila Varella-Garcia, Paul A Bunn, HER2/neu expression in malignant lung tumors. Seminars in Oncology. ,vol. 29, pp. 51- 58 ,(2002) , 10.1053/SONC.2002.31523
Andrea Ardizzoni, Mara A. Cafferata, Michela Paganuzzi, Rosangela Filiberti, Paola Marroni, Monica Neri, Vincenzo Fontana, Guido Nicol�, Luisa Perdelli, Corrado Gallo Stampino, Riccardo Rosso, Riccardo Puntoni, Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma. Cancer. ,vol. 92, pp. 1896- 1904 ,(2001) , 10.1002/1097-0142(20011001)92:7<1896::AID-CNCR1707>3.0.CO;2-0